598728 Disclosed is a sustained-release pharmaceutical dosage form adapted for oral administration to a subject in need thereof comprising a therapeutically effective amount of at least one bile acid sequestrant selected from colesevelam colesevelam hydrochloride and sevelamer a therapeutically effective amount of at least one proton pump inhibitor and a gastric-retention vehicle composition comprising one or more hydrogels wherein said dosage form is adapted for use in preventing or treating an...

Disclosed is a sustained-release pharmaceutical dosage form adapted for oral administration to a subject in need thereof, comprising a therapeutically effective amount of at least one bile acid sequestrant selected from colesevelam and colesevelam hydrochloride and a gastric-retention vehicle composition comprising one or more hydrogels, wherein said dosage form is adapted for use in preventing or treating an esophageal disorder selected from heartburn, erosive esophagitis, GERD, esophagitis, Ba...

The present invention relates to pharmaceutical compositions comprising polyallylamine polymer, binder, disintegrant, diluents and pharmaceutically acceptable inert excipients, substantially free of cellulose or cellulose derivatives and stearic acid. The polyallylamine polymer includes such as sevelamer hydrochloride, sevelamer carbonate and colesevelam hydrochloride. Particularly, the present invention provides pharmaceutical composition comprising a tablet core substantially free of cellulose...

Disclosed herein are pharmaceutical compositions comprising wet granulated bile acid sequestrants having the general Formula I shown, and their process of preparation. The present invention also discloses process for preparation of Colesevelam hydrochloride, an antilipemic agent.

A method for treating hyperglycemia and/or reducing serum glucose levels in a patient that includes administering to the patient a therapeutically effective amount of an amine polymer is disclosed. In one embodiment the amine polymer is aliphatic. Examples of polymers useful in an embodiment of the invention include sevelamer hydrogen chloride and colesevelam. The invention includes the use of amine polymers such as a cross-linked polymer characterized by a repeat unit having the formula: and sa...

This document relates to methods and materials for administering bile acid sequestrants to treat conditions associated with diarrhea. For example, formulations designed for the delivery of a bile acid sequestrant (e.g., colesevelam) to treat diarrhea are provided.

A method and a composition for making a composition, tablet, or tablet core having cross-linked polyallylamine salts such as sevelamer hydrochloride, sevelamer carbonate, or colesevelam hydrochloride, that may be used for treating hyperphosphatemia or reducing cholesterol. The method involves blending of a cross-linked polyallylamine salt with a water soluble excipient, optionally with water, an additive and/or a lubricant, and further tableting the resulting blend to form tablets and tablet cor...

A method and a composition for making a composition, tablet, or tablet core having cross-linked polyallylamine salts such as sevelamer hydrochloride, sevelamer carbonate, or colesevelam hydrochloride, that may be used for treating hyperphosphatemia or reducing cholesterol. The method involves blending of a cross-linked polyallylamine salt with a water soluble excipient, optionally with water, an additive and /or a lubricant, and further tableting the resulting blend to form tablets and tablet co...